Skip to Main Content

Paper Details

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
J Clin Oncol
45
2024
Author NameAffiliation
Funda Meric-BernstamUniversity of Texas MD Anderson Cancer Center
  • 1 - 1

Datasets

Release 1.2